Glutamate-related pathways

Glutamate is the primary excitatory neurotransmitter in the mammalian central nervous system, mediating the majority of fast excitatory synaptic transmission and playing a vital role in synaptic plasticity, learning, and memory (StatPearls, 2023). The glutamate-related pathways comprise a diverse array of proteins, including ionotropic receptors (NMDA, AMPA, and kainate receptors), metabotropic G protein-coupled receptors (mGluRs), and excitatory amino acid transporters (EAATs) (NCBI, 2022). Dysregulation of these pathways, particularly excessive glutamate signaling leading to excitotoxicity, is a hallmark of various neurological and psychiatric conditions such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and epilepsy (PubMed, 2020). Pharmacological intervention in these pathways is common, utilizing NMDA receptor antagonists like memantine for dementia or ketamine for treatment-resistant depression, as well as AMPA receptor antagonists for seizure control (PubChem, 2024). However, because glutamate signaling is ubiquitous throughout the brain, targeting these pathways presents significant challenges in achieving therapeutic efficacy without inducing adverse effects like dissociation, sedation, or cognitive impairment.

Other names

Glutamatergic systemGlutamate signaling pathwayGlutamatergic neurotransmission

Drugs targeting these pathways primarily act through the antagonism of ionotropic receptors (e.g., NMDA or AMPA receptors) to reduce over-excitation, or by modulating glutamate release and reuptake to prevent neurotoxicity (PubChem, 2024).